Patent · US Active

Antibody drug conjugates

US10626172B2 · kind B2 · utility

0Cited by

8References

5Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Tinya Abrams · Richmond, US
Steven Bruce Cohen · San Diego, US
Jason Damiano · Oakland, US
Clemens Dürr · Weil am Rhein, DE
Thomas Huber · Basel, CH
Daniel Menezes · Berkeley, US
Kathy Miller · San Francisco, US
Katherine Rendahl · Berkeley, US
Jean-Michel Rene Rondeau · Rixheim, FR

Key dates

Filing date	May 24, 2018
Grant date	Apr 21, 2020
Priority date	—
Expiry date	May 24, 2038

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/705
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.